恩沃利单抗-话题@MedSci

#恩沃利单抗#

1篇内容 | 407人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2198984, encodeId=5c182198984f4, content=<a href='/topic/show?id=211e823029d' target=_blank style='color:#2F92EE;'>#肺腺癌#</a> <a href='/topic/show?id=a3e752852f4' target=_blank style='color:#2F92EE;'>#恩度#</a> <a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a> <a href='/topic/show?id=ccef1061227c' target=_blank style='color:#2F92EE;'>#恩沃利单抗#</a>, objectTitle=PD-L1高表达晚期肺腺癌合并恶性胸腔积液患者获益恩沃利单抗联合恩度治疗, objectType=article, longId=822000, objectId=662e822000a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-working-in-a-hospital-PSQT2U3.jpg, objectUrl=/article/show_article.do?id=662e822000a4, replyNumber=0, likeNumber=7, createdTime=2024-04-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=662e822000a4, moduleTitle=PD-L1高表达晚期肺腺癌合并恶性胸腔积液患者获益恩沃利单抗联合恩度治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662e822000a4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2130156, encodeId=c898213015687, content=<a href='/topic/show?id=404d1054e621' target=_blank style='color:#2F92EE;'>#阿得贝利单抗#</a>、<a href='/topic/show?id=9e52103953a4' target=_blank style='color:#2F92EE;'>#舒格利单抗#</a>、<a href='/topic/show?id=ccef1061227c' target=_blank style='color:#2F92EE;'>#恩沃利单抗#</a>、<a href='/topic/show?id=6bf49e844e9' target=_blank style='color:#2F92EE;'>#阿替利珠单抗#</a>和<a href='/topic/show?id=7b2910612398' target=_blank style='color:#2F92EE;'>#度伐利尤单抗#</a>, objectTitle=国内获批上市的5款PD-L1抑制剂, objectType=article, longId=764634, objectId=90abe6463416, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668018702923_4754896.png, objectUrl=/article/show_article.do?id=90abe6463416, replyNumber=0, likeNumber=53, createdTime=2023-05-05, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=90abe6463416, moduleTitle=国内获批上市的5款PD-L1抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90abe6463416)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] 侠胆医心

阿得贝利单抗、舒格利单抗、恩沃利单抗、阿替利珠单抗和度伐利尤单抗

2023-05-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肺腺癌# #恩度# #恶性胸腔积液# #恩沃利单抗#

PD-L1高表达晚期肺腺癌合并恶性胸腔积液患者获益恩沃利单抗联合恩度治疗

2024-04-17发表于陕西省

(审核中...)

前往app查看评论内容

#阿得贝利单抗#、#舒格利单抗#、#恩沃利单抗#、#阿替利珠单抗#和#度伐利尤单抗#

国内获批上市的5款PD-L1抑制剂

2023-05-05发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务